Cyclerion grants director options for 48,445 shares

Cyclerion Therapeutics director Nimish P. Shah received a long-term stock option award tied to Venrock Management’s economic interest.

Rhea-AI Filing Summary

Cyclerion Therapeutics, Inc. (CYCN) reported that director Nimish P. Shah received a grant of stock options on September 9, 2026 to acquire 48,445 shares of common stock at an exercise price of $26.20 per share. These options vest in equal monthly installments through September 9, 2029 and expire on September 9, 2036. According to an agreement with Venrock Management, LLC, the option and underlying shares are held for the sole benefit of Venrock Management, which is entitled to the underlying shares, and Shah disclaims beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

Grant/Award: 48,445 shares

Grant/Award 1 txn

Insider Shah Nimish P

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	48,445	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 48,445 contracts (Direct)

Footnotes (2)

1. F1. This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
2. F2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

Key Figures

Stock options granted: 48,445 options Exercise price: $26.20 per share Underlying common shares: 48,445 shares +3 more

6 metrics

Stock options granted 48,445 options Director grant reported for September 9, 2026

Exercise price $26.20 per share Exercise price of stock option grant

Underlying common shares 48,445 shares Shares of common stock underlying the option

Post-grant derivative holdings 48,445 options Total stock options held after the reported transaction

Option expiration date September 9, 2036 Expiration of the stock option grant

Vesting period end date September 9, 2029 End of equal monthly vesting schedule, subject to continued service

Key Terms

Stock Option (Right to Buy), vest in equal monthly installments, indirect beneficial owner, pecuniary interest, +1 more

5 terms

Stock Option (Right to Buy) financial

"The reporting person received a Stock Option (Right to Buy)"

vest in equal monthly installments financial

"The option will vest in equal monthly installments through September 9, 2029"

indirect beneficial owner financial

"The Management Company may be deemed the indirect beneficial owner"

pecuniary interest financial

"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this grant"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cyclerion Therapeutics (CYCN) report for Nimish P. Shah?

Cyclerion Therapeutics reported that director Nimish P. Shah received a stock option grant on September 9, 2026 covering 48,445 shares of common stock, with an exercise price of $26.20 per share and expiration on September 9, 2036.

How do the new stock options for Nimish P. Shah in CYCN vest?

The option to acquire 48,445 shares of Cyclerion Therapeutics common stock will vest in equal monthly installments through September 9, 2029, subject to Nimish P. Shah’s continued service to the company on each vesting date.

What is the role of Venrock Management, LLC in Nimish P. Shah’s CYCN option grant?

Under an agreement with Venrock Management, LLC, Nimish P. Shah is deemed to hold the option and underlying shares for the sole benefit of Venrock Management. Venrock Management is entitled to the underlying shares, and Shah must exercise the option only at its direction.

Does Nimish P. Shah claim full beneficial ownership of the Cyclerion (CYCN) option shares?

No. Nimish P. Shah disclaims beneficial ownership of the shares underlying the option except to the extent of his pecuniary interest in Venrock Management, LLC, which may be deemed the indirect beneficial owner of the shares.

Were the CYCN insider option transactions for Nimish P. Shah made under a Rule 10b5-1 plan?

The filing indicates that no Rule 10b5-1 trading plan is reported in connection with this stock option grant to Nimish P. Shah.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:45 PM Accepted by SEC EDGAR 09/10/2026 - 05:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Nimish P

(Last) (First) (Middle)

C/O KORSANA BIOSCIENCES, INC.

203 CRESCENT STREET, SUITE 503

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Korsana Biosciences, Inc. [ KRSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$26.2	09/09/2026		A		48,445		(1)	09/09/2036	Common Stock	48,445	$0	48,445	D(2)

Explanation of Responses:

1. This option represents the right to purchase 48,445 shares of the Issuer's common stock and will vest in equal monthly installments through September 9, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

2. Under an agreement between the Reporting Person and Venrock Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

	/s/ Mark Vignola, as attorney-in-fact for Nimish Shah	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)